Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs ATMEKSI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg,Off-label use as part of antiretroviral therapy in treatment-experienced patients with viral suppression
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
1.5 mg/kg IV every 4 weeks
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Atazanavir is metabolized by CYP3A4; cobicistat is metabolized by CYP3A and to a minor extent by CYP2D6.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
95% bound to albumin and alpha-1-acid glycoprotein.
4-6 L/kg; large Vd indicates extensive tissue distribution
2.0 L/kg, indicating extensive tissue distribution.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: 60-70% due to first-pass metabolism.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
GFR 15-29 m L/min: 1.0 mg/kg IV every 4 weeks; GFR <15 m L/min: not recommended
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh A: no adjustment; Child-Pugh B: 1.0 mg/kg IV every 4 weeks; Child-Pugh C: not recommended
Not approved for pediatric patients <18 years; safety and efficacy not established.
Age 2-17 years: 1.5 mg/kg IV every 4 weeks; maximum 120 mg per dose
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific adjustment; monitor renal function and reduce dose if GFR <30 m L/min
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hepatotoxicity, especially in patients with pre-existing liver disease or elevated transaminases,Nephrolithiasis and cholelithiasis,Cardiac conduction abnormalities (PR interval prolongation),Risk of developing resistance if not used with other antiretrovirals,Renal impairment (cobicistat decreases estimated creatinine clearance)
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Concomitant use with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, rifampin, ergot derivatives, St. John's wort, lovastatin, simvastatin, sildenafil for pulmonary arterial hypertension),Severe hepatic impairment (Child-Pugh Class B or C)
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Avoid alcohol (may exacerbate CNS effects). Grapefruit juice may increase atomoxetine exposure; limit consumption. High-fat meals do not significantly affect absorption.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis unless benefit outweighs risk.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Not recommended during breastfeeding. M/P ratio unknown. Excreted in animal milk; potential for serious adverse reactions in nursing infants.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No dose adjustment required in pregnancy. Pharmacokinetic profile unchanged.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
ATMEKSI (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) indicated for ADHD. It has a slower onset of action (2-4 weeks) compared to stimulants. Monitor for hepatotoxicity and suicidal ideation, especially in children and adolescents. Use cautiously with hepatic impairment (reduce dose) and CYP2D6 poor metabolizers (need lower dose). Avoid concurrent MAOIs. May cause orthostatic hypotension and urinary retention.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take ATMEKSI exactly as prescribed; do not change dose without consulting your doctor.,It may take 2-4 weeks to notice improvement in symptoms.,Avoid alcohol and grapefruit juice as they may affect drug levels.,Report any signs of liver problems (yellowing of skin/eyes, dark urine, abdominal pain) or suicidal thoughts immediately.,May cause dizziness or fainting, especially when standing up; rise slowly.,Do not stop abruptly without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs ATMEKSI, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. ATMEKSI is a PDE5 Inhibitor that works by ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and ATMEKSI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of ATMEKSI is: 1.5 mg/kg IV every 4 weeks. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and ATMEKSI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. ATMEKSI is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.